(RTTNews) - Dell Technologies Inc. (DELL) Wednesday said it has agreed to pay $1 billion to settle a previously reported lawsuit relating to a Class V transaction that was completed on December 28, ...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.

FAIRFAX, Va., Feb. 10, 2025 /PRNewswire/ -- Playa Hotels & Resorts N.V. (PLYA) (the "Company" or "Playa") today confirmed it has entered into an agreement with Hyatt Hotels Corporation (H) ("Hyatt") ...

SAN DIEGO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for ...